Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
R.N. Nir-Paz, J. Strahilevitz, M. Shapiro, N. Keller, A. Goldschmied-Reouven, O. Yarden, et al.
Clinical and epidemiological aspects of infections caused by Fusarium species: A collaborative study from Israel.
J Clin Microbiol., 42 (2004), pp. 3456-3461
[2.]
E.I. Boutati, E.J. Anaissie.
Fusarium, a significant emerging pathogens in patients with hematologic malignancy: Ten years experience at a cancer center and implications for management.
Blood, 90 (1997), pp. 999-1008
[3.]
R.W. Fleming, T.J. Walsh, T.J. Anaissie.
Emerging and less common fungal pathogens.
Infect Dis Clin North Am., 16 (2002), pp. 915-933
[4.]
S. Arikan, M. Lozano-Chiu, V. Paetznick, J.H. Rex.
In vitro susceptibility testing methods for caspofungin against Aspergillus and Fusarium isolates.
Antimicrob Agent Chemother., 45 (2001), pp. 327-330
[5.]
A.L. Vincent, J.E. Cabrero, J.N. Greene, R.L. Sandin.
Successful voriconazole therapy of desseminated Fusarium solani in the brain of a neutropenic cancer patient.
Cancer Control, 10 (2003), pp. 414-419
[6.]
B. Austen, H. McCarthy, B. Wilkins, A. Smith, A. Duncombe.
Fatal disseminated Fusarium infection in acute lymphoblastic leukaemia in complete remission.
J Clin Pathol., 54 (2001), pp. 488-490
[7.]
A. Reuben, E. Anaissie, P.E. Nelson, R. Hashem, C. Legrand, D.H. Ho, et al.
Antifungal susceptibility of 44 isolates of Fusarium species determined by using a broth microdilution method.
Antimicrob Agent Chemother., 33 (1989), pp. 1647-1649
Copyright © 2007. Asociación Española de Pediatría
